NASDAQ NMS - GLOBAL MARKET · CTXR
+5.74% · +$0.0322 · Vol 72.0K
Market closed · last close 4:00 PM ET · price as of 16:50:53 ET
Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc

Pharmaceuticals
$0.5935
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
HISTORY WINDOW BUILDING
AI Analysis
Sovereign

Why is CTXR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for CTXR are being assembled.
About Citius Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2011
Employees
23
Country
US

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.5612
Day high
$0.6100
Day low
$0.5612
Previous close
$0.5613
52W high
$0.6100
-2.70% from high
52W low
$0.5612
66% of range
Market cap
$16M
EPS
$-3.4000
Shares out
27.5M
Volume
72K
VWAP
$0.5771
Price history computed in-house
SMA 50 $0.5881 · above
SMA 200 $0.5881 · above
52W position 66%
Veridion warehouse edge

Warehouse intelligence for CTXR.

Veridion Score
36
0: 881: 392: 313: 84: 755: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

CTXR insider activity

Citius Pharmaceuticals Inc

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for CTXR.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

CTXR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CTXR in this window.
Lobbying spend

CTXR lobbying filings, year to date.

Registered lobbying filings matched to Citius Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CTXR in this window.
Latest news · CTXR
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for CTXR.
Options
Sovereign unlock shows live options positioning for CTXR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.